An interventional study of dexamethasone palmitate and Dexamethasone in Pain, Postoperative and Dexamethasone Palmitate, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Pain, Postoperative by Beijing Tiantan Hospital — 8 open to participants now, 9 under way, 1 of them phase 3. Pain, Postoperative · Beijing Tiantan Hospital.
Among the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2026, is one of 11 with no phase, and was the 24th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →8 of the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–64
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Beijing Tiantan Hospital · Sites in China
Ages 2–12
Beijing Tiantan Hospital
Ages 18+
Beijing Tiantan Hospital
Ages 18–64
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 13
First in 2019; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 446 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 136 across the 28 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
3 of the studies in Pain, Postoperative by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06406829Beijing Tiantan HospitalPerioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy | 2026-12-31 |
| NCT07591233Beijing Tiantan HospitalPre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Laparoscopic Surgery | 2027-03-10 |
| NCT07341854Beijing Tiantan HospitalDexamethasone Palmitate for Postoperative Pain | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative pain remains highly prevalent and inadequately managed in a significant proportion of surgical patients, often leading to delayed recovery, increased opioid consumption, and potential progression to chronic pain. While perioperative systemic dexamethasone is used for its anti-inflammatory and opioid-sparing effects, its efficacy is inconsistent, and concerns regarding systemic side effects persist. Dexamethasone palmitate, a novel lipophilic prodrug formulated as nanoparticle emulsion, leverages the enhanced permeability and retention effect to target inflammatory sites selectively, potentially offering superior anti-inflammatory and analgesic efficacy with reduced systemic exposure. This trial aims to evaluate whether preoperative intravenous dexamethasone palmitate is more effective than conventional dexamethasone in preventing moderate-to-severe postoperative pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4)Classified as (ASA) physical status I, II, or III.
5) Willingness to participate voluntarily and provide written .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients assigned to the dexamethasone palmitate group will receive an intravenous injection of 8 mg dexamethasone palmitate after induction of anaesthesia but prior to surgical incision.
Drug: dexamethasone palmitate
Patients in the dexamethasone group will receive an intravenous injection of 8 mg dexamethasone after induction of anaesthesia but prior to surgical incision.
Drug: Dexamethasone
Patients assigned to the dexamethasone palmitate group will receive an intravenous injection of 8 mg dexamethasone palmitate after induction of anaesthesia but prior to surgical incision.
Patients in the dexamethasone group will receive an intravenous injection of 8 mg dexamethasone after induction of anaesthesia but prior to surgical incision.
The percentage of participants experiencing moderate to severe pain
The percentage of participants experiencing moderate to severe pain (Visual Analog Scale \[VAS\]\>30 mm)
Time frame: 24 hours after surgery
Cumulative opioid consumption
Cumulative opioid consumption, expressed as morphine milligram equivalents (MME)
Time frame: At 6, 24, 48, and 72 hours postoperatively
The total consumption of supplemental oxycodone/paracetamol tablets
The total consumption of supplemental oxycodone/paracetamol tablets, expressed as the number of tablets
Time frame: At 6, 24, 48, and 72 hours postoperatively
The proportion of participants experiencing moderate to severe pain
The proportion of participants experiencing moderate to severe pain at rest and during passive movement (e.g., coughing, deep breathing, or following a 5 m walk test)
Time frame: At 6, 24, 48, and 72 hours postoperatively
Time to first patient-controlled analgesia (PCA) bolus request
Time to first PCA bolus request
Time frame: Within the first 72 hours postoperatively
Participant satisfaction with pain management
Using a 0-10 point numerical rating scale (NRS) (0 = very dissatisfied to 10 = most satisfied imaginable)
Time frame: At 6, 24, 48, and 72 hours postoperatively and at discharge
Incidences of postoperative nausea and vomiting (PONV)
PONV is defined as any nausea, vomiting, retching, or combination thereof. Nausea refers to an unpleasant sensation associated with the urge to vomit; vomiting is defined as the forceful expulsion of gastric contents; and retching indicates an involuntary attempt to vomit without producing gastric contents.
Time frame: At 6, 24, 48, and 72 hours after surgery
Quality of recovery
Quality of recovery will be measured using the 15-item quality of recovery scoring system \[QoR-15\] questionnaire. The total score ranges from 0 to 150, where higher scores indicate a better quality of recovery.
Time frame: At 24, 48, and 72 hours postoperatively, as well as at 1 month after surgery.
Length of hospital stay
Length of hospital stay was defined as the number of days from the date of hospital admission to the date of discharge.
Time frame: From the date of hospital admission to the date of discharge, assessed throughout the hospitalization period (up to 1 month).
Incidence of postoperative adverse events
This outcome measure assesses the occurrence of specified safety events within six month after surgery. The number of participants experiencing any of the following confirmed events will be recorded and reported based on clinical examination, medical record review, and necessary laboratory tests: hypotension, hypertension, gastrointestinal ulcers, poor wound healing, surgical site infection, urinary retention, and hyperglycemia. Data will be aggregated and reported as event frequency and participant count.
Time frame: Within six month after surgery
Pain intensity
(0 = no pain, 100mm = worst imaginable pain)
Time frame: upon arrival in the PACU after the patient becomes conscious (0 hour), and at 6, 24, 48, and 72 hours postoperatively, as well as at discharge, and at 1 month, 3 month, and 6 month follow up.
total PCA attempts
Participant' total PCA attempts patients' total PCA attempts patients' total PCA attempts
Time frame: Within the first 72 hours postoperatively
Plan to share: Yes — All personal identifiers will be stored securely by the principal investigator, separate from the pseudonymized study data. Access is restricted to the research team, and all published findings will be based on anonymized data aggregates.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 14 months is above that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone palmitate